Key result
Fenofibrate (160 mg/day) significantly increased adiponectin levels by 7.7% compared to 1.8% with placebo (P=0.0005) in patients with hypertriglyceridemia and metabolic syndrome.
Why the study?
Does fenofibrate increase adiponectin levels and reduce inflammatory markers in patients with hypertriglyceridemia and metabolic syndrome?
RCT (n=55)
Randomized
Does fenofibrate increase adiponectin levels and reduce inflammatory markers in patients with hypertriglyceridemia and metabolic syndrome?
Absolute Event Rate: 7.7% vs 1.8%
p-value: p=0.0005
Fenofibrate increases adiponectin levels in patients with metabolic syndrome, which correlates inversely with multiple inflammatory markers, suggesting a potential mechanism for its anti-inflammatory effects.
No takes yet. Share an insight, caveat, or question.
Fenofibrate modestly raises adiponectin in metabolic syndrome; leaves open whether this drives anti-inflammatory effects in larger trials.
Robert S. Rosenson (2008) conducted an RCT in Hypertriglyceridemia and metabolic syndrome (n=55). Fenofibrate vs. Placebo was evaluated on Change in adiponectin levels (p=0.0005). Fenofibrate (160 mg/day) significantly increased adiponectin levels by 7.7% compared to 1.8% with placebo (P=0.0005) in patients with hypertriglyceridemia and metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: